DNA testing is getting more popular, and interest in investing in genetics is trending up as well. While a lot of the most popular names in home DNA test kits, like 23andme and Ancestry, aren't yet publicly traded, there are still plenty of companies that let you invest on the trend. There are also new IPOs in this field, with via a merger with VG Acquisition (VGAC).
Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in dna testing stocks.
1 - 7 of 7
*Signup bonus information updated weekly.
Take a deeper dive into dna testing stocks
If you're interested in investing in the genetic testing industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.
1. Natera (NTRA)
Natera, Inc. , a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Natera stock opened the day at $117.90 after a previous close of $117.29. The latest price was $120.94 (25-minute delay). Natera is listed on the NASDAQ, has a trailing 12-month revenue of around USD931 million and employs 2,958 staff.
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies stock opened the day at $4.05 after a previous close of $4.05. The latest price was $4.18 (25-minute delay). Genetic Technologies is listed on the NASDAQ, has a trailing 12-month revenue of around USD$10.3 million and employs 60 staff.
VG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
VG Acquisition stock opened the day at $10.99 after a previous close of $10.99. The latest price was $10.99 (25-minute delay). VG Acquisition is listed on the NYSE.
Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Sangamo Therapeutics stock opened the day at $12.01 after a previous close of $12.01. The latest price was $11.71 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$218.5 million and employs 478 staff.
Sign up with an online broker or platform to invest in one or more of these dna testing stocks.
Compare share trading platforms. Use our comparison table to narrow down top brokers by fees and bonuses.
Open and fund your brokerage account. You’ll need personal and financial details, like your contact and bank information.
Search for the stock you're interested in. Find the stock by name or ticker symbol, like NTRA or GENE.
Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
Choose an order type. Invest in the dna testing stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the genetic testing industry, track how your stock performs to decide when it’s time to sell.
While it’s possible to turn a profit investing in dna testing stocks, keep in mind that — like any investment — dna testing stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the genetic testing industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
How likely would you be to recommend finder to a friend or colleague?
Very UnlikelyExtremely Likely
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.